Saliva as a testing sample for SARS-CoV-2 detection by RT-PCR in low prevalence community settings

Didzis Gavars[1], Mikus Gavars[1], Dmitry Perminov[1,4], Janis Stasulans[1], Justine Stana[1], Zane Metla[1], Jana Pavare[3], Eriks Tauckels[1], Egils Gulbis[1], Uga Dumpis[2,4]

1 - E.Gulbja Laboratory, Riga, Latvia

2 - Pauls Stradins Clinical University Hospital, Riga Latvia

3 - Children's Clinical University Hospital, Riga Stradins University, Riga, Latvia

4 - University of Latvia, Riga, Latvia

Corresponding author:

Dr. Didzis Gavars, E.Gulbja Laboratory

Brivibas str.366, Riga, Latvia, LV-1006

email: didzis@egl.lv;

telephone: +37129259742; fax: +37167543867

Abstract

Objectives

The number of COVID-19 cases is increasing globally and there is an urgency for a simple non-invasive method for the detection of SARS-CoV-2. Our study aimed to demonstrate that saliva can be used as a specimen for SARS-CoV-2 detection notably for the screening of extensive population groups via pooling.

Methods

To demonstrate that saliva is an appropriate specimen for SARS-CoV-2 detection a field study including 3,660 participants was performed between September 29 and October 1, 2020. We collected paired nasopharyngeal/oropharyngeal swabs (NPS) and saliva specimens and processed them within 24 hours of collection. We performed 36 serial measurements of 8 SARS-CoV-2 positive saliva samples to confirm the stability of the specimen and completed 37 pools of saliva samples by adding one positive specimen per pool.

Results

Saliva specimens were stable for testing for up to 24 hours. Overall, 44 salival samples (1.2%) tested positive for SARS-CoV-2 during the field study. The results of saliva samples were consistent with those obtained from NPS from the same patient with 90% sensitivity (95% CI 68.3%-98.7%) and 100% specificity during the first two weeks after the onset of symptoms. Using pooling strategy 796 RT-PCR tests were performed. All pools showed 100% positivity in different pooling proportions.

Conclusions

Our findings demonstrate that saliva is an appropriate specimen for pooling and SARS-CoV-2 screening with accurate diagnostic performance. Patient-performed simple specimen collection allows testing an extensive number of people rapidly, obtaining results of the spread of SARS-CoV-2 and allowing authorities to take timely measures.

Introduction

Since the beginning of 2020 massive resources have been dedicated to control and mitigate the COVID-19 pandemic. Testing capacity and accessibility are crucial in monitoring COVID-19 outbreaks and allowing for the adjustment of measures put into place to reduce community transmission (1).

Viral nucleic acid detection using the real-time polymerase chain reaction (RT-PCR) assay remains the gold standard for the detection of SARS-CoV-2 and to diagnose COVID-19 (2). Due to the increased demand for sampling and testing materials globally considerable constraints remain to conduct widespread screening for SARS-CoV-2. It is especially challenging for counties with low prevalence levels as global suppliers allocate materials and decide delivery schedules based on the prevalence of the virus.

Shortages of supplies and medical staff, logistical hurdles, as well the unpleasantness associated with obtaining a RT-PCR specimen making it difficult to practice the procedure on children and causing irritation for those who need to undergo repeated tests, all these factors have naturally accelerated research into alternative specimens and sampling methods for COVID-19 testing (3,4).

On September 21, 2020, Latvia had a 14-day cumulative number of COVID-19 cases of 5.1 per 100,000 people. By October 10 that number had risen to 66. During this period, laboratories experienced a significant overload (5). Rapid and efficient solutions to increase testing capacity were needed.

The objective of this study was to confirm that saliva is a suitable specimen comparable to a nasopharyngeal/oropharyngeal swab for SARS-CoV-2 detection in specific populations. We also evaluated the pooling approach to employ it in field conditions for extensive screening of high-risk groups.

Methods

Patient sample collection

A single-center study was performed including all consented patients attending the laboratory for SARS-CoV-2 testing between May 12 and October 19, 2020. For the collection of the saliva samples, self-collection kits were distributed consisting of a specimen vial, registration form, alcohol pads for disinfection, and two safety plastic bags. Patients were requested to collect their saliva in an isolated location (keeping at least five meters distance from other persons or objects), preferably outdoors, at home, or in their car. The saliva was collected in a container without any additive and delivered to the laboratory within 24 hours. Paired nasopharyngeal/oropharyngeal swabs (NPS) for RT-PCR were collected using the standard method used in our laboratory (6).

Sample preparation and analysis using RT-PCR

96 Immediately upon arrival at the laboratory, the samples were
97 pretreated by adding 1 ml of phosphate-buffered saline (PBS). The
98 extraction of RNA and RT-PCR testing was identical for both swab
99 and pre-treated saliva samples. Viral RNA was extracted with standard
100 commercial extraction methods (QIAGEN, Germany and LifeRiver,
101 China) used in our laboratory. RT-PCR was performed using our
102 laboratory-developed and validated test method which detects S and N
103 genes of the SARS-CoV-2 virus. Our validated and verified limit of
104 detection (LOD) was 1 cp/rxn.

105

106 **Results**

107 ***Stability of saliva specimens***

108 To confirm the stability of saliva samples, we performed 36 serial tests
109 on 8 primary SARS-CoV-2 positive saliva samples collected from
110 patients 48 hours after their NPS tested positive. The data are
111 summarized in Tables 1-3. Testing was randomized by different time
112 intervals, the time of day, and the shifts of technicians. It includes
113 repeated testing of two samples after 22h (Table 2) and serial repeats
114 of one sample (Table 3) with Ct value reporting.

115 All results confirmed a positive result after 22-25h of the first test
116 being conducted. Samples were stored refrigerated at 2-6ºC between
117 tests.

118 ***Comparison of saliva and nasopharyngeal/oropharyngeal samples***

119 Between May 13 and September 21, 2020, 431 tests on saliva samples
120 were performed, and the results were compared with paired NPS RT-
121 PCR test results. Using NPS RT-PCR as the reference, there were

104 PCR positive samples and 327 negative patients, including 125 pediatric (age 5-17 years (average 11.3 years)) samples. The observed RT-PCR positive results were divided into groups according to the number of days after the onset of symptoms: 0-14 days (22 patients); 15-30 days (52 patients); 31-70 days (20 patients) and 10 asymptomatic patients. The results of the comparison of the mentioned subgroups are presented in Table 4.

Sensitivity and specificity for the respective groups were: for 0-14 days 90% (95%CI 68.3%-98.7%) and 100% (95%CI 22.4%-100%); for 15-30 days 64.7% (95% CI 46.5%-80.3%) and 83.3% (95%CI 58.9%-96.4%); for 31-70 days 71.4% (95%CI 29.0%-96.3%) and 84.6% (95%CI 54.6%-98.1%); for asymptomatic 71.4% (95%CI 29.0%-96.3%) and 66.7% (95%CI 0.8%-90.6%). The mean Ct values for the groups were 33.9 for NPS and 33.8 for saliva (0-14 days), 34.8 for NPS and 34 for saliva (15-30 days), and 36.5 for NPS and 39 for saliva in the asymptomatic patient group.

Pooling of saliva

To evaluate the testing of pooled saliva samples, 37 pools were constituted. There were 15 pools of 5 samples (4 negatives + 1 positive), 13 pools of 10 samples (9 negatives + 1 positive), and 9 pools of 20 samples (19 negatives + 1 positive). The RT-PCR testing for each pool was repeated twice. The total number of measurements was 74. All results were 100% positive.

When using pooling, the number of tests needed per sample was calculated as follows: the total number of tests needed to test all samples is divided by the total number of samples. For example, if

500 samples are being tested in pools of 10, it means 50 tests are initially needed. With a positivity rate of 1%, a maximum of five pools will contain a positive specimen (if each positive sample is in a different pool). The 50 samples from these five pools will have to be retested individually (each of the five positive pools contains 10 samples). Therefore, a total of 100 tests are needed to evaluate all 500 samples and the number of tests per sample is 100/500 = 0.2.

The positivity rate in Latvia on September 23, 2020, was 0.5%.

The approximate positivity rate at which the pooling of 5 samples becomes more efficient than the pooling of 10 samples is 3% (2-4% depending on test price, laboratory load, tests per sample).

Field study

To evaluate the convenience of saliva pool testing by RT-PCR in field conditions, the town of Kuldiga (total population 10,352) with an ongoing outbreak of COVID-19 in a textile factory was selected. In collaboration with local authorities, 4,100 saliva self-sampling kits were distributed to inhabitants at a specially established distribution point. There were four persons dedicated to the distribution of the kits and four drivers to deliver the samples by car to the testing laboratory in Riga (150 km one way). During the study period, 3,660 saliva samples were collected (response rate 91.5%), delivered to the laboratory, and tested in pools of 10 samples. There were a total of 366 pools. In the first round of testing 43 pools were found to be positive and samples from these pools were re-tested individually. The saliva samples from 44 patients were confirmed as positive by RT-PCR. Mean Ct values of pooled samples were 13% higher than

174 individually tested Ct (31.6 versus 27.6). The positivity rate of the
175 tested population was 1.2%. In total 796 RT-PCR tests were
176 performed. At the time of the sample collection, 68.2% (30/44) of
177 patients did not report any symptoms on the questionnaire form.

178 Nasopharyngeal swab tests and saliva tests were compared with the
179 number of new COVID-19 cases. The findings illustrate that the
180 second peak in new cases occurred 6-7 days after the initial peak. Such
181 findings correspond with the mean incubation period of the SARS-
182 CoV-2. The results reflect a decrease in new cases in the following
183 observation period (Figure 1).

184

185 **Discussion**

186 The findings of our study can be summarized as follows: (a) for the
187 detection of SARS-CoV-2, saliva is a stable specimen with acceptable
188 specificity and sensitivity at the early stages of infection; (b) saliva
189 specimen is appropriate for pooling, with accurate diagnostic
190 performance.
191 Saliva has been identified as a reliable testing specimen for SARS-
192 CoV-2 using the RT-PCR approach in several recent studies (7–9). In
193 the updated European Centre for Disease Prevention and Control
194 (ECDC) recommendations, saliva is also mentioned as a convenient
195 specimen for SARS-CoV-2 testing (10,11). The FDA has approved
196 methods for SARS-CoV-2 testing using saliva in several laboratories
197 (12,13). Nevertheless, saliva has been included in IFCC COVID-19
198 Guidelines on Molecular, Serological, and
199 Biochemical/Haematological Testing as a promising sample type (14).

200 The high expression of ACE2 receptors in salivary gland cells is the
201 main factor for virus affinity that could lead to active replication and
202 transmission by saliva droplets expelled into the air during coughing
203 or sneezing (15,16).

204 It is essential to establish standardized sample collection procedures,
205 safe logistics, and reliable testing methods that meet performance
206 requirements. Our stability testing confirmed that saliva samples
207 stayed equally positive up to 24h.

208 In the analytical context, saliva can have the same or even better
209 performance than NPS (17). It has been previously confirmed to be
210 highly sensitive and specific at the early stage of infection 0-14 days
211 after onset of symptoms and in asymptomatic cases (17,18). Therefore,
212 it is essential to take into consideration the relationship between the
213 dynamics of viral load, Ct values, and the number of days after the
214 onset of symptoms. As described in prior publications, the Ct value is
215 important in determining the infectiousness of a patient sample. Ct
216 values above 34 do not emit infectious virus particles, and values
217 between 27-34 show low viability of the viral load. Samples with a Ct
218 value of 13-17 show positive virus viability (19). Ct values may vary
219 depending on the different assays by up to 5 cycles for the same sample
220 (20). Variation also appears due to the quality of the specimen obtained
221 and the different treatment methods used to prepare samples for testing
222 (21). As expected, we got some variation between the NPS and saliva
223 sample types. In our pilot testing using 44 positive saliva samples we
224 found slightly higher (13%) Ct values in pools, compared to individual
225 tests. Similar findings have been published by other researchers (22).
226 This observed slight difference still allows for the safe use of saliva

227 pooling for surveillance purposes with sufficient diagnostic accuracy.
228 Nevertheless, pooling strategies are described in the latest update of
229 COVID-19 testing strategies and objectives published by the ECDC
230 (11). There is evidence of benefits from pooling in low prevalence
231 countries with a low proportion of positive samples – up to 5%. Recent
232 publications indicate that for populations with a prevalence of less than
233 1% the testing of saliva pools of 10 or 20 samples is more beneficial,
234 and our independent calculations also bear this out. Comparing the
235 correlation between different pool sizes (usefulness and efficiency)
236 with test positivity rate, we concluded that a pool size of 10 is more
237 efficient than a pool size of 5. The calculations are based on test price,
238 reimbursement conditions, and the number of tests per sample (when
239 using a pooling strategy) (23,24).

240 The pooling strategy for self-collected saliva samples is the optimal
241 solution that saves resources and reduces the testing time (25). In our
242 real-life field test on a "perifocal" population, we successfully tested
243 nearly a third of the citizens of the town of Kuldiga in three days. This
244 allowed for fast identification of asymptomatic SARS-CoV-2 cases
245 and those with mild symptoms to enable timely contact tracing and
246 outbreak containment. The use of nasopharyngeal swabs in such a
247 situation would have required more staff and time with possible patient
248 compliance issues.

249 Additionally, improvements may reasonably be expected in terms of
250 organizing the distribution of self-sampling kits to patients as well as
251 the logistics of returning the kits to the laboratory that would further
252 increase the usefulness of screening using a pooled testing strategy.

There were some limitations in our study: the size of the cohort of participants was limited, the selected laboratory-developed RT-PCR method for evaluation was used, also a lack of multicenter observation. Future studies extending the cohort are needed to confirm current findings and provide the implications in clinical practice.

Conclusions

Our findings confirm the stability of SARS-CoV-2 RNA in saliva, showing acceptable performance in terms of specificity and sensitivity at the early stages of infection, and the advantages of testing using a pooling strategy in a low prevalence population. Ct values and detected/missing gene information are favorable for the interpretation of the results from several aspects, e.g. epidemiological investigation, determination if the patient is infectious at the current stage, etc. Self-sampling makes the procedure faster, safer, and requires fewer resources. The targeted distribution of test kits among a population with a known outbreak significantly increased the positivity rate. Saliva pool testing on a large scale provides an additional tool to take timely measures and contain outbreaks.

Ethical aspects

The study was approved by the Ethics Committee of the Pauls Stradins Clinical University Hospital (record No 300720-18L).

Acknowledgments

We gratefully acknowledge all participants for their commitment to participate and their time. Special thanks to all trial team members in the E.Gulbja Laboratory for their dedication and work which made this study possible and Dr. A.Gramatniece for editorial help.

Author contributions

Gavars D - the conception and design of the study, Gavars M, Perminovs D, and Metla Z – validation of the method and interpretation of the data, Stasulans J, Stana J - patient recruitment and data collection, drafting of the article, Tauckels E - data analysis, Gulbis E, and Dumpis U – revising the article critically, final approval of the version to be submitted.

Transparency declaration

All authors declare that there are no conflicts of interest.

Funding institution:

Ministry of Education and Science, Republic of Latvia. Funding number: VPP-COVID-2020/1-0008.

Additional funding was provided by E.Gulbja laboratory.

References:

1. Rapid Risk Assessment: Coronavirus disease 2019 (COVID-19) in the EU/EEA and the UK– ninth update [Internet]. European

302 Centre for Disease Prevention and Control. 2020 [cited 2020 Nov
303 16]. Available from: https://www.ecdc.europa.eu/en/publications-
304 data/rapid-risk-assessment-coronavirus-disease-2019-covid-19-
305 pandemic-ninth-update
306 2. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in
307 suspected human cases [Internet]. [cited 2020 Nov 16]. Available
308 from: https://www.who.int/publications-detail-redirect/10665-
309 331501
310 3. COVID-19: Overcoming supply shortages for diagnostic testing |
311 McKinsey [Internet]. [cited 2020 Nov 16]. Available from:
312 https://www.mckinsey.com/industries/pharmaceuticals-and-
313 medical-products/our-insights/covid-19-overcoming-supply-
314 shortages-for-diagnostic-testing#
315 4. Jeong HW, Kim S-M, Kim H-S, Kim Y-I, Kim JH, Cho JY, et al.
316 Viable SARS-CoV-2 in various specimens from COVID-19
317 patients. Clin Microbiol Infect. 2020 Nov;26(11):1520–4.
318 5. COVID-19 situation update for the EU/EEA and the UK, as of 16
319 November 2020 [Internet]. European Centre for Disease
320 Prevention and Control. [cited 2020 Nov 16]. Available from:
321 https://www.ecdc.europa.eu/en/cases-2019-ncov-eueea
322 6. Marty FM, Chen K, Verrill KA. How to Obtain a Nasopharyngeal
323 Swab Specimen. N Engl J Med. 2020 May 28;382(22):e76.
324 7. Fakheran O, Dehghannejad M, Khademi A. Saliva as a diagnostic
325 specimen for detection of SARS-CoV-2 in suspected patients: a
326 scoping review. Infect Dis Poverty. 2020 Jul 22;9(1):100.
327 8. Hamid H, Khurshid Z, Adanir N, Zafar MS, Zohaib S. COVID-19
328 Pandemic and Role of Human Saliva as a Testing Biofluid in
329 Point-of-Care Technology. Eur J Dent [Internet]. 2020 Jun 3 [cited

330 2020 Nov 16]; Available from: http://www.thieme-
331 connect.de/DOI/DOI?10.1055/s-0040-1713020
332 9. Czumbel LM, Kiss S, Farkas N, Mandel I, Hegyi A, Nagy Á, et
333 al. Saliva as a Candidate for COVID-19 Diagnostic Testing: A
334 Meta-Analysis. Front Med. 2020 Aug 4;7:465–465.
335 10. Objectives for COVID-19 testing in school settings - first update,
336 21 August 2020. Tech Rep. 2020;4.
337 11. COVID-19 testing strategies and objectives [Internet]. European
338 Centre for Disease Prevention and Control. 2020 [cited 2020 Nov
339 16]. Available from: https://www.ecdc.europa.eu/en/publications-
340 data/covid-19-testing-strategies-and-objectives
341 12. Commissioner O of the. Coronavirus (COVID-19) Update: FDA
342 Authorizes First Diagnostic Test Using At-Home Collection of
343 Saliva Specimens [Internet]. FDA. FDA; 2020 [cited 2020 Nov
344 16]. Available from: https://www.fda.gov/news-events/press-
345 announcements/coronavirus-covid-19-update-fda-authorizes-
346 first-diagnostic-test-using-home-collection-saliva
347 13. Rutgers Launches Genetic Testing Service for New Coronavirus |
348 Rutgers University [Internet]. [cited 2020 Nov 16]. Available
349 from: https://www.rutgers.edu/news/rutgers-launches-genetic-
350 testing-service-new-coronavirus
351 14. Bohn M, Mancini N, Loh P, Wang C-B, Grimmler M, Gramegna
352 M, et al. IFCC interim guidelines on molecular testing of SARS-
353 CoV-2 infection. Clin Chem Lab Med. 2020 Oct 7;
354 15. Liu L, Wei Q, Alvarez X, Wang H, Du Y, Zhu H, et al. Epithelial
355 Cells Lining Salivary Gland Ducts Are Early Target Cells of
356 Severe Acute Respiratory Syndrome Coronavirus Infection in the

357 Upper Respiratory Tracts of Rhesus Macaques. J Virol. 2011 Apr
358 15;85(8):4025–30.
359 16. Xu J, Li Y, Gan F, Du Y, Yao Y. Salivary Glands: Potential
360 Reservoirs for COVID-19 Asymptomatic Infection. J Dent Res.
361 2020;99(8):989.
362 17. Wyllie AL, Fournier J, Casanovas-Massana A, Campbell M,
363 Tokuyama M, Vijayakumar P, et al. Saliva or Nasopharyngeal
364 Swab Specimens for Detection of SARS-CoV-2. N Engl J Med.
365 2020;4.
366 18. Zhang W, Du R-H, Li B, Zheng X-S, Yang X-L, Hu B, et al.
367 Molecular and serological investigation of 2019-nCoV infected
368 patients: implication of multiple shedding routes. Emerg Microbes
369 Infect. 2020 Feb 17;9(1):386–9.
370 19. La Scola B, Le Bideau M, Andreani J, Hoang VT, Grimaldier C,
371 Colson P, et al. Viral RNA load as determined by cell culture as a
372 management tool for discharge of SARS-CoV-2 patients from
373 infectious disease wards. Eur J Clin Microbiol Infect Dis. 2020
374 Apr 27;1–3.
375 20. Nalla AK, Casto AM, Huang M-LW, Perchetti GA, Sampoleo R,
376 Shrestha L, et al. Comparative Performance of SARS-CoV-2
377 Detection Assays Using Seven Different Primer-Probe Sets and
378 One Assay Kit. J Clin Microbiol. 2020 26;58(6).
379 21. Rodino KG, Espy MJ, Buckwalter SP, Walchak RC, Germer JJ,
380 Fernholz E, et al. Evaluation of Saline, Phosphate-Buffered
381 Saline, and Minimum Essential Medium as Potential Alternatives
382 to Viral Transport Media for SARS-CoV-2 Testing. McAdam AJ,
383 editor. J Clin Microbiol. 2020 May 26;58(6):e00590-20.

22. Lohse S, Pfuhl T, Berkó-Göttel B, Rissland J, Geißler T, Gärtner B, et al. Pooling of samples for testing for SARS-CoV-2 in asymptomatic people. Lancet Infect Dis. 2020 Nov 1;20(11):1231–2.
23. Regen F, Eren N, Heuser I, Hellmann-Regen J. A simple approach to optimum pool size for pooled SARS-CoV-2 testing. Int J Infect Dis. 2020 Nov 1;100:324–6.
24. Mutesa L, Ndishimye P, Butera Y, Souopgui J, Uwineza A, Rutayisire R, et al. A pooled testing strategy for identifying SARS-CoV-2 at low prevalence. Nature. 2020 Oct 21;1–8.
25. Fogarty A, Joseph A, Shaw D. Pooled saliva samples for COVID-19 surveillance programme. Lancet Respir Med. 2020;8(11):1078–80.


N - performed tests daily
N - confirmed new cases daily
1800
1600
1400
1200
1000
800
600
400
200
0
70
60
50
40
30
20
10
0
16/09
17/09
18/09
19/09
20/09
21/09
22/09
23/09
24/09
25/09
26/09
27/09
28/09
29/09
30/09
01/10
02/10
03/10
04/10
05/10
06/10
07/10
08/10
09/10
10/10
11/10
12/10
13/10
14/10
15/10
16/10
17/10
18/10
NPS - SARS-CoV-2 positive
Saliva samples - SARS-CoV-2 positive
NPS - total
Saliva samples - total

Table 1 Run No. 1 on saliva stability measurements of 5 samples collected 2-4h before the first testing

	0	**after 8h**	**after 24h**	**after 25h**
	1st 14:00	*2nd 22:00*	*3rd 14:00*	*4th 15:00*
1	Positive	Positive	Positive	Positive
2	Positive	Positive	Positive	Positive
3	Positive	W- Positive	Positive	W- Positive
4	Positive	Positive	Positive	No sample left
5	Positive	W- Positive	Positive	W- Positive

Abbreviations: W-Positive - weak positive result, h - hours

Table 2 Run No. 2 on saliva stability serial measurements of two samples collected 2-4h before first testing

	0	**after 12h**	**after 22h**	**after 22h rep.**
	1st 12:00	*2nd 00:00*	*3rd 10:00*	*4th 10:00*
6	W- Positive	Positive	Positive	Positive
Ct	35	36	37	37
7	Positive	Positive	Positive	Positive
Ct	32	33	30	31

Abbreviations: W-Positive - weak positive result, rep. - repeats, h – hours

Table 3 Run No. 3 on saliva repeatability measurements of one sample collected 2 - 4h before the first testing with indicated Ct values

	0	**after 3h**	**after 12h**	**after 24h**
	1st 11:00	*2nd 14:00*	*3rd 02:00*	*4th 11:00*
8	Positive	Positive	Positive	Positive
Ct	34	30	33	35
8 rep.	Positive	Positive	Positive	Positive
Ct	34	27	31	35

Abbreviations: rep. - repeats, h – hours

Table 4 Saliva samples compared to the results of nasopharyngeal/ oropharyngeal swabs

		NPS							
Days after the start of symptoms		0-14		15-30		31-70		Asymptomatic	
RT-PCR		Positive	Negative	Positive	Negative	Positive	Negative	Positive	Negative
Saliva	Positive	18	0	22	3	5	2	5	1
	Negative	2	2	12	15	2	11	2	2
Sensitivity %		90		64.7		71.4		71.4	
Specificity %		100		83.3		84.6		66.7	

Abbreviations: NPS - nasopharyngeal/ oropharyngeal swabs, RT-PCR – real-time polymerase chain reaction